

Product datasheet for KN215665BN

GPR161 Human Gene Knockout Kit (CRISPR)

Product data:

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 mBFP-Neo donor, 1 scramble control
Donor DNA:	mBFP-Neo
Symbol:	GPR161
Locus ID:	23432
Components:	 KN215665G1, GPR161 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002) KN215665G2, GPR161 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002) KN215665BND, donor DNA containing left and right homologous arms and mBFP-Neo functional cassette. GE100003, scramble sequence in pCas-Guide vector
Disclaimer:	These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
RefSeq:	<u>NM 001267609, NM 001267610, NM 001267611, NM 001267612, NM 001267613, NM 001267614, NM 007369, NM 153832, NM 001349632, NM 001349633, NM 001349634, NM 001349635</u>
UniProt ID:	<u>Q8N6U8</u>
Synonyms:	RE2
Summary:	The protein encoded by this gene is an orphan G protein-coupled receptor whose ligand is unknown. This gene is overexpressed in triple-negative breast cancer, and disruption of this gene slows the proliferation of basal breast cancer cells. Therefore, this gene is a potential drug target for triple-negative breast cancer. [provided by RefSeq, Mar 2017]



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2025 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

Product images:



RFP, Luc, and mBFP will be under native gene promoter

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2025 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US